In light of evidence from recent studies that HLA-G is a potent regulator of host immune defenses in patients with cancer and its impact in CRC survival [46,49], we hypothesized that HLA-G might confer tolerance to the inflammatory/immune status induced by drug treatments in CRC. The gene discussed is HLA-G; the disease is cancer.